Molecular Cancer (Jan 2022)

On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial

  • Tao Jiang,
  • Jianhua Chen,
  • Xingxiang Xu,
  • Ying Cheng,
  • Gongyan Chen,
  • Yueyin Pan,
  • Yong Fang,
  • Qiming Wang,
  • Yunchao Huang,
  • Wenxiu Yao,
  • Rui Wang,
  • Xingya Li,
  • Wei Zhang,
  • Yanjun Zhang,
  • Sheng Hu,
  • Renhua Guo,
  • Jianhua Shi,
  • Zhiwu Wang,
  • Peiguo Cao,
  • Donglin Wang,
  • Jian Fang,
  • Hui Luo,
  • Yi Geng,
  • Chunyan Xing,
  • Dongqing Lv,
  • Yiping Zhang,
  • Junyan Yu,
  • Shundong Cang,
  • Yaxi Zhang,
  • Jiao Zhang,
  • Zeyu Yang,
  • Wei Shi,
  • Jianjun Zou,
  • Caicun Zhou,
  • Shengxiang Ren

DOI
https://doi.org/10.1186/s12943-021-01479-4
Journal volume & issue
Vol. 21, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Background Camrelizumab plus chemotherapy significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to chemotherapy alone as first-line treatment in advanced lung squamous cell carcinoma (LUSC) in the phase III trial (CameL-sq), which has become an option of standard-of-cares for Chinese patients with advanced LUSC. However, the predictive biomarkers remain unknown. Methods Tumor tissue samples at baseline, and peripheral blood samples at baseline (pretreatment) and after two cycles of treatment (on-treatment) were prospectively collected from 270 LUSC patients from the CameL-sq study. Blood tumor mutation burden (bTMB) and its dynamics were analyzed to explore their predictive values. Results Pretreatment bTMB was not associated with objective response, PFS and OS in camrelizumab or placebo plus chemotherapy groups. Low on-treatment bTMB was associated with significantly better objective response (73.8% vs 27.8%, P < 0.001), PFS (median, 9.1 vs 4.1 months; P < 0.001) and OS (median, not reached vs 8.0 months; P < 0.001) in camrelizumab plus chemotherapy group whereas it did not correlate with objective response and PFS in chemotherapy alone group. Importantly, on-treatment bTMB level could discriminate patients of initially radiological stable disease who would long-term benefit from camrelizumab plus chemotherapy (low vs high, median OS, 18.2 vs 7.8 months; P = 0.001). Combing on-treatment bTMB and its dynamics improved the ability for predicting the efficacy of camrelizumab plus chemotherapy. Conclusion On-treatment bTMB together with its dynamics could serve as a predictive biomarker for camrelizumab plus chemotherapy in patients with advanced LUSC. Trial registration ClinicalTrials.gov identifier: NCT03668496.

Keywords